Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:PGEN 15 August 2025 - 14 November 2025

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

The FDA approved Papzimeos, the first immunotherapy for recurrent respiratory papillomatosis, after trials showed 51.4% of adults avoided surgery for 12 months. Cardinal Health will acquire Solaris Health for $1.9 billion in cash, expanding its specialty care network. RemeGen’s telitacicept met its Phase 3 endpoint in primary Sjögren’s syndrome in China. Response Therapeutics’ RDX-002 pill curbed weight regain in a Phase 2 trial.
15 August 2025
···

Stock Market Today

  • Silicon Motion (SIMO) Rises Despite Market Downturn, Strong Earnings Anticipated
    March 19, 2026, 7:45 PM EDT. Silicon Motion (SIMO) closed up 1.67% at $127.50, outperforming the S&P 500's 0.28% decline. Despite a 5.54% drop over the past month, SIMO is set for a significant earnings report, with analysts predicting $1.23 per share - a 105% year-over-year surge. Revenue is expected to reach $299.61 million, up nearly 80% from last year. Full-year projections show earnings of $5.8 per share and revenues hitting $1.27 billion, marking growth of 63% and 43% respectively. The stock holds a Zacks Rank #1 (Strong Buy), with recent upward estimate revisions signaling confidence. SIMO trades at a forward price-to-earnings (P/E) ratio of 21.61, slightly above its industry average, and maintains a PEG ratio of 0.77, matching its sector. The Computer - Integrated Systems industry ranks in the top 10%, underpinning favorable future performance prospects.
Go toTop